Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: Relevance to clinical interaction with fluconazole

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 924-926

  Trapnell, Carol Braun ^a   Jamis Dow, Carlos ^a   Klecker, Raymond W ^a   Collins, Jerry M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYTOCHROME P450; DRUG METABOLITE; FLUCONAZOLE; KETOCONAZOLE; LM 565; QUINIDINE SULFATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIFABUTIN; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0030999969     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.924     Document Type: Article

References (24)

1. Anaissie, E. J., D. P. Kontoyiannia, C. Huls, S. E. Vartivarian, C. Karl, R. A. Prince, J. Bosso, and G. P. Bodey. 1995. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis., 172:599-602.
2. Benedetti, M. S., and P. Dostert. 1994. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102:101-105.
3. Benedetti, M. S., C. Efthymiopoulos, D. Sassella, E. Moro, and M. Repetto. 1990. Autoinduction of rifabutin metabolism in man. Xenobiotica 20:1113-1119.
4. Chang, T. K. H., F. J. Gonzalez, and D. J. Waxman. 1994. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethytdithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311:437-442.
5. Frank, M. O., M. B. Graham, and B. Wispelway. 1994. Rifabutin and uveitis. N. Engl. J. Med. 330:868. (Letter.)
6. Fuller, J. D., L. E. D. Stanfield, and D. E. Craven. 1994. Rifabutin prophylaxis and uveitis. N. Engl. J. Med. 330:1315-1316. (Letter.)
7. Gallant, J. E., R. D. Moore, and R. E. Chaisson. 1994. Prophylaxis for opportunistic infections in patients with HIV infection. Ann. Intern. Med. 120:932-944.
8. Havlir, D., F. Torriani, and M. Dubé. 1994. Uveitis associated with rifabutin prophylaxis. Ann. Intern. Med. 121:510-512.
9. Honig, P. K., D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena, Jr. 1993. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
10. Jamis-Dow, C. A., R. W. Klecker, A. G. Katki, and J. M. Collins. 1995. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chcmother. Pharmacol. 36:107-114.
11. Lewis, R. C., N. Z. Hatfield, and P. K. Narang. 1991. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biologic fluids by high-performance liquid chromatography (HPLC). Pharm. Res. 8:1434-1440.
12. Maurice, M., L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel. 1992. Effects of imidazole derivatives on cytochrome p450 from human hepatocytes in primary culture. FASEB J. 6:752-758.
13. Monahan, B. P., C. L. Ferguson, E. S. Killeavy, B. K. Lloyd. J. Troy, and L. R. Cantilena, Jr. 1990. Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
14. Morrow, J. D. 1991. Fluconazole: a new triazole antifungal agent. Am. J. Med. Sci. 302:129-132.
15. Narang, P. K., C. B. Trapnell, J. E. Schoenfelder, J. P. Lavelle, and J. R. Bianchine. 1994. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330:1316-1317. (Letter.)
16. Nightingale, S. D., D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn, R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, J. J. Stern, D. D. Pearce, W. G. Weinberg, A. LaMarca, and F. P. Siegal. 1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med. 329:828-833.
17. Perucca, E., R. Grimaldi, G. M. Frigo, A. Sardi, H. Mönig, and E. E. Ohnhaus. 1988. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol. 34:595-599.
18. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. Frame, W. He, C. van der Horst, S. L. Koletar, E. Eyster, J. Carey, H. Waskin, T. M. Hooton, N. Hyslop, S. A. Spector, and S. A. Bozette for the NIAID AIDS Clinical Trials Group. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
19. Shafran, S. D., J. Deschênes, M. Miller, P. Phillips, and E. Toma for the MAC Study Group of Canadian HIV Trials Network. 1994. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethamhutol. N. Engl. J. Med. 330:438-439. (Letter.)
20. Skinner, M. H., and T. F. Blaschke. 1995. Clinical pharmacokinetics of rifabutin. Clin. Pharmacokinet. 28:115-125.
21. Skinner, M. H., M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen, T. C. Merigan, and T. F. Blaschke. 1989. Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33:1237-1241.
22. Trapnell, C. B., P. K. Narang. R. Li, and J. P. Lavelle. 1996. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med. 124:573-576.
23. Tsao, S. C., T. H. Dickinson, and D. R. Abernethy. 1990. Metabolite inhibition of parent drug transformation. Studies of diltiazem. Drug Metab. Dispos. 18:180-182.
24. Wallace, R. J., Jr., B. A. Brown, D. E. Griffith, W. Girard, and K. Tanaka. 1995. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 171:747-750.